A locus and mechanism of action for associative morphine tolerance

Nature Neuroscience

Volumn 3, Issue 1, 2000, Pages 47-53

  Mitchell, Jennifer M ^a   Basbaum, Allan I ^a   Fields, Howard L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; CHOLECYSTOKININ; CHOLECYSTOKININ B RECEPTOR; MORPHINE; OPIATE;

AMYGDALOID NUCLEUS; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HIPPOCAMPUS; MALE; MORPHINE TOLERANCE; NONHUMAN; PRIORITY JOURNAL; RAT;

AMYGDALA; ANIMALS; ASSOCIATION LEARNING; BENZODIAZEPINONES; DEVAZEPIDE; DRUG TOLERANCE; HIPPOCAMPUS; HORMONE ANTAGONISTS; IMMUNOHISTOCHEMISTRY; MALE; MICROINJECTIONS; MORPHINE; NARCOTICS; NEURONS; ONCOGENE PROTEINS V-FOS; PAIN MEASUREMENT; PHENYLUREA COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CHOLECYSTOKININ A; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ;

EID: 0034001105     PISSN: 10976256     EISSN: None     Source Type: Journal    
DOI: 10.1038/71120     Document Type: Article

References (50)

1. Faris, P. L., Komisaruk, B. R., Watkins, L. R. & Mayer, D. I. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 219, 310-312 (1983).
2. 2 with mu and delta opioid antinociception in the rat spinal cord. Neuropeptides 16, 213-218 (1990).
3. Watkins L. R., Kinscheck, I. B. & Mayer, D. J. Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. Science 224, 395-396 (1984).
4. Katsuura, G. & Itoh, S. Potentiation of β-endorphin effects by proglumide in rats. Eur. J. Pharmacol. 107, 363-366 (1985).
5. Dourish, C. T. et al. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur. J. Pharmacol. 176, 35-44 (1990).
6. Zhou, Y., Sun, Y. H., Zhang, Z. W. & Han, J. S. Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of μ-opioid analgesia by CCKB receptor antagonist L-365,260 in the rat spinal cord. Eur. J. Pharmacol. 234, 147-154 (1993).
7. Valverde, O., Maldonado, R., Fournie-Zaluski, M. C. & Roques, B. P. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J. Pharmacol. Exp. Ther. 270, 77-88 (1994).
8. Vanderah, T. W., Bernstein, R. N., Yamamura, H. I., Hruby, V. J. & Porecca, F. Enhancement of morphine antinociception by a CCKB antagonist in mice is mediated via opioid delta receptors. J. Pharmacol. Exp. Ther. 278, 212-219 (1996).
9. Chapman, V., Honore, P., Buritova, J. & Besson, J. M. Cholecystokinin B receptor antagonism enhances the ability of a low dose of morphine to reduce c-fos expression in the spinal cord of the rat. Neuroscience 67, 731-739 (1995).
10. Kellstein, D. E., Price, D. D. & Mayer, D. J. Cholecystokinin and its antagonist lorglumide respectively attenuate and facilitate morphine-induced inhibition of C-fiber evoked discharges of dorsal horn nociceptive neurons. Brain Res. 540, 302-306 (1991).
11. Tang, J., Chou, J., Iadarola, M., Yang, H. Y. T. & Costa, E. Proglumide prevents and curtails acute tolerance to morphine in rats. Neuropharmacology 23, 715-718 (1984).
12. Dourish, C. T., Hawley, D. & Iversen, S. D. Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718. Eur. J. Pharmacol. 147, 469-472 (1988).
13. Xu, X. J., Wiesenfeld-Hallin, Z., Hughes, J., Horwell, D. C. & Hokfelt, T. CI988, a selective antagonist of cholecystokinin B receptors prevents morphine tolerance in the rat. Br. J. Pharmacol. 105, 591-596 (1992).
14. Panerai, A. E., Rovati, L. C., Cocco, E., Sacerdote, P. & Mantegazza, P. Dissociation of tolerance and dependence to morphine: a possible role for cholecystokinin. Brain Res. 410, 52-60 (1987).
15. Baber, N. S., Dourish, C. T. & Hill, D. R. The role of CCK, caerulein, and CCK antagonists in nociception. Pain 39, 307-328 (1989).
16. Maldonado, R., Valverde, O., Derrien, M., Tejedor-Real, P. & Roques, B. P. Effects induced by BC 264, a selective agonist of CCK-B receptors, on morphine-dependent rats. Pharmacol. Biochem. Behav. 48, 363-369 (1994).
17. Branchereau, P., Champagnat, J. & Denavit-Saubie, M. Cholecystokinin-gated currents in neurons of the rat solitary complex in vitro. J. Neurophysiol. 70, 2584-2595 (1993).
18. Shigeyoshi, Y. et al. Distribution of mRNA for CCK-B receptor in the brain of Mastomys natalensis: abundant expression in telencephalic neurons. Brain Res. 640, 81-92 (1994).
19. Crawley, J. N. & Corwin, R. L. Biological actions of cholecystokinin. Peptides 15, 731-755 (1994).
20. Mercer, L. D. et al. On the distribution of cholecystokinin B receptors in monkey brain. Brain Res. 738, 313-318 (1996).
21. O'Brien, C. P., O'Brien, T. J., Mintz, J. & Brady, J. P. Conditioning of narcotic abstinence symptoms in human subjects. Drug Alcohol Depend. 1, 115-123 (1975).
22. Siegel, S. Morphine analgesic tolerance: Its situation specificity supports a pavlovian conditioning model. Science 193, 323-325 (1976).
23. Siegel, S., Hinson, R. E. & Krank, M. D. Morphine-induced attenuation of morphine tolerance. Science 212, 1533-1534 (1981).
24. Siegel, S., Hinson, R. E., Krank, M. D. & McCully, J. Heroin "overdose" death: contribution of drug-associated environmental cues. Science 216, 436-437 (1982).
25. Siegel, S. Pavlovian conditioning and heroin overdose: reports by overdose victims. Bull. Psychonomic Soc. 22, 428-430 (1984).
26. O'Brien, C. P., Ehrman, R. N. & Ternes, J. W. in Behavioral Analysis of Drug Dependence (eds. Goldberg, S. R. & Stolerman, I. P.) 329-356 (Academic, Orlando, 1986).
27. O'Brien, C. P., Childress, A. R., Ehrman, R. & Robbins, S. J. Conditioning factors in drug abuse: can they explain compulsion? J. Psychopharmacol. 12, 15-22 (1998).
28. Matthes, H. W. D. et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383, 819-823 (1996).
29. Carter, B. L. & Tiffany, S. T. Cross-tolerance of associative and nonassociative morphine tolerance in the rat with mu- and kappa-specific opioids. Psychopharmacology 123, 289-296 (1996).
30. Reum, T., Schafer, U., Marsden, C. A., Fink, H. & Morgenstern, R. CCK increases extracellular dopamine overflow in the anterior nucleus accumbens via CCK(B) receptors in the VTA assessed by in vivo voltammetry. Neuropeptides 31, 82-88 (1997).
31. Le Doux, J. E. in Mind and Brain: Dialogues in Cognitive Neuroscience (eds. LeDoux, J. E. & Hirst, W.) 301-354 (Cambridge Univ. Press, Cambridge, UK, 1986).
32. LeDoux, J. E., Iwata, J., Cicchetti, P. & Reis, D. J. Different projections of the central amygdaloid nucleus mediate autonomie and behavioral correlates of conditioned fear. J. Neurosci. 8, 2517-2529 (1988).
33. McGaugh, J. L. & Cahill, L. Interaction of neuromodulatory systems in modulating memory storage. Behav. Brain Res. 83, 31-38 (1997).
34. Jones, B. & Mishkin, M. Limbic lesions and the problem of stimulus-reinforcement associations. Exp. Neurol. 36, 362-377 (1972).
35. Spiegler, B. J. & Mishkin, M. Evidence for the sequential participation of inferior temporal cortex and amygdala in the acquisition of stimulus-reward associations. Behav. Brain Res. 3, 303-317 (1981).
36. Rolls, E. T. in The Amygdaloid Complex (ed. Ben-Ari, Y.) 383-393 (Elsevier, New York, 1981).
37. Rolls, E. T. in Emotions: Neuronal and Chemical Control (ed. Oomur, Y.) 325-344 (Japan Scientific Societies Press, New York, 1986).
38. Introini-Collison, I. B., Nagahara, A. H. & McGaugh, J. L. Memory enhancement with intra-amygdala post-training naloxone is blocked by concurrent administration of propranolol. Brain Res. 476, 94-101 (1989).
39. Belcheva, I., Belcheva, S., Petkov, V. V. & Petkov, V. D. Asymmetry in behavioral responses to cholecystokinin microinjected into rat nucleus accumbens and amygdala. Neuropharmacology 33, 995-1002 (1994).
40. Huston, J. P. et al. Modulation of memory, reinforcement and anxiety parameters by intra-amygdala injection of cholecystokinin-fragments Boc-CCK-4 and CCK-8s. Peptides 19, 27-37 (1998).
41. Pu, S., Zhuang, H., Lu, Z., Wu, X. & Han, J. Cholecystokinin gene expression in rat amygdaloid neurons: normal distribution and effect of morphine tolerance. Brain Res. Mol. Brain Res. 21, 183-189 (1994).
42. Alvarez, P., Zola-Morgan, S. & Squire, L. R. Damage limited to the hippocampal region produces long-lasting memory impairment in monkeys. J. Neurosci. 15, 3796-3807 (1995).
43. Morris, R. G. & Frey, U. Hippocampal synaptic plasticity: role in spatial learning or the automatic recording of attended experience? Phil. Trans. R. Soc. Lond. B Biol. Sci. 352, 1489-1503 (1997).
44. Reed, J. M. & Squire, L. R. Impaired recognition memory in patients with lesions limited to the hippocampal formation. Behav. Neurosci. 111, 667-675 (1997).
45. Lemaire, M., Bohme, G. A., Piot, O., Roques, B. P. & Blanchard, J. C. CCK-A and CCK-B selective receptor agonists and antagonists modulate olfactory recognition in male rats. Psychopharmacology 115, 435-440 (1994).
46. Young, B. J., Otto, T., Fox, G. D. & Eichenbaum H. Memory representation within the parahippocampal region. J. Neurosci. 17, 5183-5195 (1997).
47. Amaral, D. G. in Excitatory Amino Acids and Epilepsy (eds. Schwarcz, R. & Ben-Ari, Y.) 3-17 (Plenum, New York, 1986).
48. Saunders, R. C. & Rosene, D. L. A comparison of the efferents of the amygdala and the hippocampal formation in the rhesus monkey: I. convergence in the entorhinal, prorhinal, and perirhinal cortices. J. Comp. Neurol. 271, 153-184 (1988).
49. White, N. M. Addictive drugs as reinforcers: multiple partial actions on memory systems. Addiction 91, 921-949 (1996).
50. Llewellyn-Smith, I. J., Pilowsky, P. & Minson, J. B. The tungstate-stabilized tetramethylbenzidine reaction for light and electron microscopic immunocytochemistry and for revealing biocytin-filled neurons. J. Neurosci. Methods 46, 27-40 (1993).